Edition:
United Kingdom

Molecular Medicine SpA (MLMD.MI)

MLMD.MI on Milan Stock Exchange

0.41EUR
20 Aug 2018
Change (% chg)

€-0.00 (-1.08%)
Prev Close
€0.42
Open
€0.42
Day's High
€0.42
Day's Low
€0.41
Volume
676,289
Avg. Vol
1,675,341
52-wk High
€0.60
52-wk Low
€0.40

Latest Key Developments (Source: Significant Developments)

MolMed Signs Agreement For Development And Supply Of Lentiviral Vectors
Friday, 13 Jul 2018 

(Reuters) - MolMed ::SAID ON FRIDAY SIGNED A NEW, THREE-YEAR AGREEMENT FOR THE DEVELOPMENT AND SUPPLY OF LENTIVIRAL VECTORS.MOLMED WILL PROVIDE GSK WITH VECTORS FOR THE ONCOLOGY FIELD.  Full Article

MolMed Q1 Net Loss Narrows to EUR 1.2 Mln
Friday, 11 May 2018 

May 14 (Reuters) - MolMed ::REPORTED ON FRIDAY Q1 NET LOSS OF EUR 1.2 MLN VS LOSS EUR 3.7 MLN YEAR AGO.Q1 OPERATING REVENUE OF EUR 5.8 MLN VS EUR 4.4 MLN YEAR AGO.  Full Article

MolMed Starts Collaboration With Orchard Therapeutics For Rare Diseases
Thursday, 12 Apr 2018 

April 12 (Reuters) - Molecular Medicine SpA ::STARTS COLLABORATION WITH ORCHARD THERAPEUTICS ON GENE THERAPY FOR RARE DISEASES.  Full Article

Molmed FY Net Loss Shrinks To EUR 8.5 Mln
Friday, 9 Mar 2018 

March 12 (Reuters) - MOLMED SPA ::REPORTED ON FRIDAY FY TOTAL OPERATING REVENUES EUR 24.0 MLN VS EUR 22.8 MLN YEAR AGO.FY NET LOSS EUR 8.5 MLN VS LOSS EUR 13.9 MLN YEAR AGO.  Full Article

MolMed: Zalmoxis Can Be Reimbursed In Germany For EUR 163,900 Per Infusion
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - MOLECULAR MEDICINE SPA ::SAYS THAT AS OF JAN 15 ZALMOXIS CAN BE PRESCRIBED AND REIMBURSED IN GERMANY AT THE PRICE OF EUR 163,900 PER INFUSION.APPROVED DOSAGE FORESEES ONE OR MORE INFUSIONS, UP TO A MAXIMUM OF FOUR, TILL IMMUNE-RECONSTITUTION IS ACHIEVED.MOLMED WILL BE RESPONSIBLE FOR THE PRODUCTION AND SUPPLY OF ZALMOXIS, WHILE DOMPÉ FARMACEUTICI WILL CONDUCT ACTIVITIES AIMED AT MARKETING THE THERAPY IN GERMANY.DOMPÉ WILL PAY MOLMED A PURCHASE PRICE PROPORTIONAL TO THE REIMBURSED PRICE OF THE PRODUCT.  Full Article

Molmed Q3 net loss narrows to EUR 1.6‍​ mln
Monday, 6 Nov 2017 

Nov 6 (Reuters) - MOLECULAR MEDICINE SPA ::Q3 OPERATING REVENUE EUR ‍​6.2 MILLION VERSUS EUR 3.7 MILLION YEAR AGO.Q3 NET LOSS EUR 1.6‍​ MILLION VERSUS LOSS EUR 5.9 MILLION YEAR AGO.  Full Article

MolMed announces review of strategic agreement with GlaxoSmithKline
Thursday, 1 Sep 2016 

MolMed SpA : Announces amendment of strategic agreement signed with GlaxoSmithKline (GSK) on March 19, 2015 . Agreement relates to MolMed's supply of services for the clinical application of gene therapies based on viral vector cellular transduction until March 31, 2020 . To be eligible, through the 5 year-period covered by the contract, for minimum anticipated revenues of 48 million euros ($53.73 million) from prior 34 million euros .Of minimum anticipated revenues of 48 million euros, around 14 million euros have already been received.  Full Article

Italy - Factors to watch on July 30

The following factors could affect Italian markets on Monday.